What's new

Capvaxive® 21-valent pneumococcal conjugate vaccine

From 1 July 2026, the 21-valent pneumococcal conjugate vaccine (21vPCV), Capvaxive® will be introduced on the National Immunisation Program (NIP) for eligible adults and replace Prevenar 13® and Pneumovax 23®.

Capvaxive® is designed to protect against 21 pneumococcal serotypes which cause most of the invasive pneumococcal disease in adults in a single dose vaccine. It is registered for use in people aged 18 years and over.

Capvaxive®, is recommended and free through the NIP for:

• adults aged 65 years and over
• Aboriginal and Torres Strait Islander adults aged 25 years and over
• adults aged 18 years and over with specified medical conditions that increase their risk of severe disease.

For further vaccine information, go to:

• Pneumococcal disease Australian Immunisation Handbook - Australian Centre for Disease control website
• Adult pneumococcal vaccination - Australian Government Department of Health, Disability and Ageing website.

Previous updated vaccine information

• Respiratory syncytial virus (RSV) - 15 May 2026
• Pneumococcal vaccine - 1 September 2025
• Meningococcal B vaccine - 1 Jan 2025

For information on other National Immunisation Program (NIP) vaccines please refer to the Australian Immunisation Handbook in Australian Government's Department of Health, Disability and Ageing website.